Immune Targeting of Mycobacteria through Cell Surface Glycan Engineering
ACS Chemical Biology · 2023
DOI: 10.1021/acschembio.3c00155 ↗At a glance
Journal article in ACS Chemical Biology, 2023. Written by Priscilla Dzigba and 6 co-authors. Institution: Department of Chemistry and Biochemistry, Central Michigan University, Mount Pleasant, Michigan 48859, United States. Major MEDLINE topics: Mycobacterium, Tuberculosis, Mycobacterium tuberculosis. Cited 10 times so far (Crossref); 64 references. The full text is freely available in PubMed Central. Funded by: NIAID NIH HHS, NIGMS NIH HHS, National Institute of Allergy and Infectious Diseases.
Abstract (original language)
Mycobacteria and other organisms in the order Mycobacteriales cause a range of significant human diseases, including tuberculosis, leprosy, diphtheria, Buruli ulcer, and non-tuberculous mycobacterial (NTM) disease. However, the intrinsic drug tolerance engendered by the mycobacterial cell envelope undermines conventional antibiotic treatment and contributes to acquired drug resistance. Motivated by the need to augment antibiotics with novel therapeutic approaches, we developed a strategy to specifically decorate mycobacterial cell surface glycans with antibody-recruiting molecules (ARMs), which flag bacteria for binding to human-endogenous antibodies that enhance macrophage effector functions. Mycobacterium-specific ARMs consisting of a trehalose targeting moiety and a dinitrophenyl hapten (Tre-DNPs) were synthesized and shown to specifically incorporate into outer-membrane glycolipids of Mycobacterium smegmatis via trehalose metabolism, enabling recruitment of anti-DNP antibodies to the mycobacterial cell surface. Phagocytosis of Tre-DNP-modified M. smegmatis by macrophages was significantly enhanced in the presence of anti-DNP antibodies, demonstrating proof-of-concept that our strategy can augment the host immune response. Because the metabolic pathways responsible for cell surface incorporation of Tre-DNPs are conserved in all Mycobacteriales organisms but absent from other bacteria and humans, the reported tools may be enlisted to interrogate host-pathogen interactions and develop immune-targeting strategies for diverse mycobacterial pathogens.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- Department of Chemistry and Biochemistry, Central Michigan University, Mount Pleasant, Michigan 48859, United States.
- Department of Biology, Central Michigan University, Mount Pleasant, Michigan 48859, United States.
- Biochemistry, Cell, and Molecular Biology Graduate Programs, Central Michigan University, Mount Pleasant, Michigan 48859, United States.
- Biological Sciences Department, California Polytechnic State University, San Luis Obispo, California 93407, United States.
ORCID profiles: Adrian K Rylski, Benjamin M Swarts
Funding
- NIAID NIH HHS
- NIGMS NIH HHS
- National Institute of Allergy and Infectious Diseases
- National Institute of General Medical Sciences
Cite
APA
Dzigba, P., Rylski, A. K., Angera, I. J., Banahene, N., Kavunja, H. W., Greenlee-Wacker, M. C., & Swarts, B. M. (2023). Immune Targeting of Mycobacteria through Cell Surface Glycan Engineering. ACS Chemical Biology. https://doi.org/10.1021/acschembio.3c00155
Vancouver
Dzigba P, Rylski AK, Angera IJ, Banahene N, Kavunja HW, Greenlee-Wacker MC, et al. Immune Targeting of Mycobacteria through Cell Surface Glycan Engineering. ACS Chemical Biology. 2023. doi:10.1021/acschembio.3c00155
BibTeX
@article{Dzigba2023,
author = {Dzigba, Priscilla and Rylski, Adrian K and Angera, Isaac J and Banahene, Nicholas and Kavunja, Herbert W and Greenlee-Wacker, Mallary C and Swarts, Benjamin M},
title = {Immune Targeting of Mycobacteria through Cell Surface Glycan Engineering},
journal = {ACS Chemical Biology},
year = {2023},
doi = {10.1021/acschembio.3c00155}
}
EUVIMED